IMM vs. TRX, COS, C4XD, DDDD, OKYO, SAR, AREC, AOR, POLB, and RLM
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), OKYO Pharma (OKYO), Sareum (SAR), Arecor Therapeutics (AREC), AorTech International (AOR), Poolbeg Pharma (POLB), and Realm Therapeutics (RLM). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
ImmuPharma (LON:IMM) and Tissue Regenix Group (LON:TRX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.
Tissue Regenix Group has higher revenue and earnings than ImmuPharma. Tissue Regenix Group is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
17.4% of ImmuPharma shares are owned by institutional investors. Comparatively, 37.0% of Tissue Regenix Group shares are owned by institutional investors. 48.3% of ImmuPharma shares are owned by company insiders. Comparatively, 47.3% of Tissue Regenix Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
In the previous week, ImmuPharma's average media sentiment score of 0.00 equaled Tissue Regenix Group'saverage media sentiment score.
ImmuPharma has a net margin of 3,519.56% compared to Tissue Regenix Group's net margin of -3.46%. Tissue Regenix Group's return on equity of -2.87% beat ImmuPharma's return on equity.
ImmuPharma has a beta of 1.53, indicating that its share price is 53% more volatile than the S&P 500. Comparatively, Tissue Regenix Group has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500.
Summary
Tissue Regenix Group beats ImmuPharma on 7 of the 11 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IMM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 8/2/2025 by MarketBeat.com Staff
